Moreover, our results in vitro showed that, inhibition of EGFR by co-treatment with these drugs further enhanced CPX-induced procaspase-3 and Bcl-2 /survivin downregulation Collectively, these results indicate that CPX-enhances ROS accumulation in pancreatic cancer cells, which results in inhibition of EGFR/AKT signalling and, ultimately, cancer cell death. This evidence concerns the gene BCL2 and cancer.